Targeting TGF-β signaling in cancer

Bibliography

• Massague J. TGFbeta in cancer. Cell 2008;134(2):215-30
   PubMed Web of Science ®Google Scholar
• Mishra L, Derynck R, Mishra B. Transforming growth factor-beta signaling in stem cells and cancer. Science 2005;310(5745):68-71
   PubMedGoogle Scholar
• Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009;19(1):89-102
   PubMed Web of Science ®Google Scholar
• Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol 2011;223(2):205-18
   PubMed Web of Science ®Google Scholar
• Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425(6958):577-84
   PubMed Web of Science ®Google Scholar
• Souchelnytskyi S, Moustakas A, Heldin CH. TGF-beta signaling from a three-dimensional perspective: insight into selection of partners. Trends Cell Biol 2002;12(7):304-7
   PubMedGoogle Scholar
• Katuri V, Tang Y, Li C, et al. Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression. Oncogene 2006;25(13):1871-86
   PubMedGoogle Scholar
• Childs CB, Proper JA, Tucker RF, Moses HL. Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci USA 1982;79(17):5312-16
   PubMedGoogle Scholar
• Zu X, Zhang Q, Cao R, et al. Transforming growth factor-beta signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell Tissue Res 2012;347(1):73-84
   PubMedGoogle Scholar
• Mishra L, Shetty K, Tang Y, et al. The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005;24(37):5775-89
   PubMed Web of Science ®Google Scholar
• Keski-Oja J, Koli K, von Melchner H. TGF-beta activation by traction? Trends Cell Biol 2004;14(12):657-9
   PubMedGoogle Scholar
• Rifkin DB. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem 2005;280(9):7409-12
   PubMed Web of Science ®Google Scholar
• Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113(6):685-700
   PubMed Web of Science ®Google Scholar
• Todorovic-Rakovic N, Milovanovic J, Nikolic-Vukosavljevic D. TGF-beta and its coreceptors in cancerogenesis: an overview. Biomarkers Med 2011;5(6):855-63
   PubMedGoogle Scholar
• Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993;73(7):1435-44
   PubMed Web of Science ®Google Scholar
• Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006;107(12):4589-96
   PubMedGoogle Scholar
• Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-beta receptor. Nature 1994;370(6488):341-7
   PubMed Web of Science ®Google Scholar
• Wrana JL, Tran H, Attisano L, et al. Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex. Mol Cell Biol 1994;14(2):944-50
   PubMedGoogle Scholar
• Groppe J, Hinck CS, Samavarchi-Tehrani P, et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 2008;29(2):157-68
   PubMed Web of Science ®Google Scholar
• Tang Y, Katuri V, Dillner A, et al. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science 2003;299(5606):574-7
   PubMedGoogle Scholar
• Mishra L, Katuri V, Evans S. The role of PRAJA and ELF in TGF-beta signaling and gastric cancer. Cancer Biol Ther 2005;4(7):694-9
   PubMed Web of Science ®Google Scholar
• Mishra L, Marshall B. Adaptor proteins and ubiquinators in TGF-beta signaling. Cytokine Growth Factor Rev 2006;17(1-2):75-87
   PubMedGoogle Scholar
• Tang B, de Castro K, Barnes HE, et al. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 1999;59(19):4834-42
   PubMedGoogle Scholar
• Attisano L, Wrana JL. Mads and Smads in TGF beta signalling. Curr Opin Cell Biol 1998;10(2):188-94
   PubMedGoogle Scholar
• Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390(6659):465-71
   PubMed Web of Science ®Google Scholar
• Kretzschmar M, Massague J. SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 1998;8(1):103-11
   PubMed Web of Science ®Google Scholar
• Tang Y, Katuri V, Srinivasan R, et al. Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res 2005;65(10):4228-37
   PubMedGoogle Scholar
• Xu L. Regulation of Smad activities. Biochim Biophys Acta 2006;1759(11-12):503-13
   PubMedGoogle Scholar
• Liu F, Pouponnot C, Massague J. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev 1997;11(23):3157-67
   PubMedGoogle Scholar
• Macias-Silva M, Abdollah S, Hoodless PA, et al. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996;87(7):1215-24
   PubMedGoogle Scholar
• Souchelnytskyi S, Tamaki K, Engstrom U, et al. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 1997;272(44):28107-15
   PubMed Web of Science ®Google Scholar
• Chen Y, Lebrun JJ, Vale W. Regulation of transforming growth factor beta- and activin-induced transcription by mammalian Mad proteins. Proc Natl Acad Sci USA 1996;93(23):12992-7
   PubMedGoogle Scholar
• Hoodless PA, Haerry T, Abdollah S, et al. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 1996;85(4):489-500
   PubMedGoogle Scholar
• Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997;389(6651):618-22
   PubMed Web of Science ®Google Scholar
• Nishihara A, Hanai JI, Okamoto N, et al. Role of p300, a transcriptional coactivator, in signalling of TGF-beta. Genes Cells 1998;3(9):613-23
   PubMedGoogle Scholar
• Zhang Y, Musci T, Derynck R. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function. Curr Biol 1997;7(4):270-6
   PubMedGoogle Scholar
• Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 2012;8(7):964-78
   PubMed Web of Science ®Google Scholar
• Zhang Y, Derynck R. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol 1999;9(7):274-9
   PubMedGoogle Scholar
• Lin X, Duan X, Liang YY, et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell 2006;125(5):915-28
   PubMed Web of Science ®Google Scholar
• Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007;1775(1):21-62
   PubMed Web of Science ®Google Scholar
• Monga SP, Tang Y, Candotti F, et al. Expansion of hepatic and hematopoietic stem cells utilizing mouse embryonic liver explants. Cell Transplant 2001;10(1):81-9
   Google Scholar
• Saha T, Vardhini D, Tang Y, et al. RING finger-dependent ubiquitination by PRAJA is dependent on TGF-beta and potentially defines the functional status of the tumor suppressor ELF. Oncogene 2006;25(5):693-705
   PubMedGoogle Scholar
• Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci 2008;99(11):2107-12
   PubMed Web of Science ®Google Scholar
• Dong C, Li Z, Alvarez R Jr, et al. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 2000;5(1):27-34
   PubMedGoogle Scholar
• Wrana JL. Crossing Smads. Sci STKE 2000;2000(23):RE1
   PubMedGoogle Scholar
• Tsukazaki T, Chiang TA, Davison AF, et al. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998;95(6):779-91
   PubMedGoogle Scholar
• Zhang Y, Chang C, Gehling DJ, et al. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 2001;98(3):974-9
   PubMed Web of Science ®Google Scholar
• Mishra L, Tully RE, Monga SP, et al. Praja1, a novel gene encoding a RING-H2 motif in mouse development. Oncogene 1997;15(19):2361-8
   PubMedGoogle Scholar
• Chen HB, Shen J, Ip YT, Xu L. Identification of phosphatases for Smad in the BMP/DPP pathway. Genes Dev 2006;20(6):648-53
   PubMedGoogle Scholar
• Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009;19(1):128-39
   PubMed Web of Science ®Google Scholar
• Grady WM, Rajput A, Myeroff L, et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998;58(14):3101-4
   PubMedGoogle Scholar
• Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006;17(1-2):41-58
   PubMed Web of Science ®Google Scholar
• Akiyama Y, Iwanaga R, Saitoh K, et al. Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology 1997;112(1):33-9
   PubMed Web of Science ®Google Scholar
• Grady WM, Myeroff LL, Swinler SE, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999;59(2):320-4
   PubMed Web of Science ®Google Scholar
• Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268(5215):1336-8
   PubMed Web of Science ®Google Scholar
• Takenoshita S, Tani M, Nagashima M, et al. Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene 1997;14(10):1255-8
   PubMedGoogle Scholar
• Parsons R, Myeroff LL, Liu B, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995;55(23):5548-50
   PubMed Web of Science ®Google Scholar
• Wang D, Kanuma T, Mizunuma H, et al. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res 2000;60(16):4507-12
   PubMed Web of Science ®Google Scholar
• Goggins M, Shekher M, Turnacioglu K, et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998;58(23):5329-32
   PubMed Web of Science ®Google Scholar
• Chen T, Yan W, Wells RG, et al. Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases. Int J Cancer 2001;93(5):653-61
   PubMed Web of Science ®Google Scholar
• Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86(4):543-52
   PubMedGoogle Scholar
• Yakicier MC, Irmak MB, Romano A, et al. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999;18(34):4879-83
   PubMedGoogle Scholar
• Maliekal TT, Antony ML, Nair A, et al. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene 2003;22(31):4889-97
   PubMedGoogle Scholar
• Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271(5247):350-3
   PubMed Web of Science ®Google Scholar
• Miyaki M, Iijima T, Konishi M, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999;18(20):3098-103
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29(2):117-29
   PubMed Web of Science ®Google Scholar
• Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56(11):2527-30
   PubMed Web of Science ®Google Scholar
• Nagatake M, Takagi Y, Osada H, et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 1996;56(12):2718-20
   PubMedGoogle Scholar
• Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13(3):343-6
   PubMed Web of Science ®Google Scholar
• Hahn SA, Bartsch D, Schroers A, et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998;58(6):1124-6
   PubMedGoogle Scholar
• Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998;280(5366):1086-8
   PubMed Web of Science ®Google Scholar
• Gomis RR, Alarcon C, He W, et al. A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci USA 2006;103(34):12747-52
   PubMedGoogle Scholar
• Pardali K, Kurisaki A, Moren A, et al. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 2000;275(38):29244-56
   PubMed Web of Science ®Google Scholar
• Seoane J, Le HV, Shen L, et al. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004;117(2):211-23
   PubMed Web of Science ®Google Scholar
• Staller P, Peukert K, Kiermaier A, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001;3(4):392-9
   PubMed Web of Science ®Google Scholar
• Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002;419(6908):729-34
   PubMedGoogle Scholar
• Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003;3(11):807-21
   PubMed Web of Science ®Google Scholar
• Jang CW, Chen CH, Chen CC, et al. TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 2002;4(1):51-8
   PubMed Web of Science ®Google Scholar
• Boulanger CA, Wagner KU, Smith GH. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene 2005;24(4):552-60
   PubMedGoogle Scholar
• Glick AB, Weinberg WC, Wu IH, et al. Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res 1996;56(16):3645-50
   PubMedGoogle Scholar
• Kirshner J, Jobling MF, Pajares MJ, et al. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res 2006;66(22):10861-9
   PubMedGoogle Scholar
• Bornstein S, White R, Malkoski S, et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest 2009;119(11):3408-19
   PubMed Web of Science ®Google Scholar
• Joseph H, Gorska AE, Sohn P, et al. Overexpression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching. Mol Biol Cell 1999;10(4):1221-34
   PubMedGoogle Scholar
• Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303(5659):848-51
   PubMed Web of Science ®Google Scholar
• Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146
   PubMed Web of Science ®Google Scholar
• Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108(4):601-9
   PubMed Web of Science ®Google Scholar
• Chen CR, Kang Y, Siegel PM, Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 2002;110(1):19-32
   PubMedGoogle Scholar
• Latres E, Malumbres M, Sotillo R, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 2000;19(13):3496-506
   PubMedGoogle Scholar
• Chen CR, Kang Y, Massague J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 2001;98(3):992-9
   PubMedGoogle Scholar
• Gomis RR, Alarcon C, Nadal C, et al. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 2006;10(3):203-14
   PubMedGoogle Scholar
• Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994;54(24):6353-8
   PubMedGoogle Scholar
• Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008;133(1):66-77
   PubMed Web of Science ®Google Scholar
• DeCoteau JF, Knaus PI, Yankelev H, et al. Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997;94(11):5877-81
   PubMedGoogle Scholar
• Rooke HM, Vitas MR, Crosier PS, Crosier KE. The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression. Leukemia 1999;13(4):535-41
   PubMedGoogle Scholar
• Capocasale RJ, Lamb RJ, Vonderheid EC, et al. Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sezary patients. Proc Natl Acad Sci USA 1995;92(12):5501-5
   PubMedGoogle Scholar
• Fernandez T, Amoroso S, Sharpe S, et al. Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J Exp Med 2002;195(10):1247-55
   PubMedGoogle Scholar
• Mori N, Morishita M, Tsukazaki T, et al. Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through interaction with CREB-binding protein/p300. Blood 2001;97(7):2137-44
   PubMedGoogle Scholar
• Kurokawa M, Mitani K, Irie K, et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998;394(6688):92-6
   PubMedGoogle Scholar
• Jakubowiak A, Pouponnot C, Berguido F, et al. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 2000;275(51):40282-7
   PubMed Web of Science ®Google Scholar
• Inman GJ. Switching TGFbeta from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 2011;21(1):93-9
   PubMedGoogle Scholar
• Adorno M, Cordenonsi M, Montagner M, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009;137(1):87-98
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol 2007;9(9):1000-4
   PubMedGoogle Scholar
• Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12(1):22-9
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139(5):871-90
   PubMed Web of Science ®Google Scholar
• Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009;19(2):156-72
   PubMed Web of Science ®Google Scholar
• Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007;98(10):1512-20
   PubMed Web of Science ®Google Scholar
• Valcourt U, Kowanetz M, Niimi H, et al. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 2005;16(4):1987-2002
   PubMed Web of Science ®Google Scholar
• Cheng N, Chytil A, Shyr Y, et al. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 2008;6(10):1521-33
   PubMedGoogle Scholar
• Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133(4):704-15
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7(10):1118-22
   PubMed Web of Science ®Google Scholar
• Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8(5):369-80
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Hurd SD, Winnier AR, et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Investig 1993;92(6):2569-76
   PubMedGoogle Scholar
• Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004;172(12):7335-40
   PubMedGoogle Scholar
• Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003;100(7):4120-5
   PubMed Web of Science ®Google Scholar
• Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010;10(8):554-67
   PubMed Web of Science ®Google Scholar
• Hagedorn HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review). Int J Oncol 2001;18(4):669-81
   PubMedGoogle Scholar
• Porsch H, Bernert B, Mehić M, et al. Efficient TGFβ-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene 2012; doi: 10.1038/onc.2012.475. [Epub ahead of print]
   PubMedGoogle Scholar
• Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3(6):537-49
   PubMed Web of Science ®Google Scholar
• Sanchez-Elsner T, Botella LM, Velasco B, et al. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001;276(42):38527-35
   PubMed Web of Science ®Google Scholar
• Larsson J, Goumans MJ, Sjostrand LJ, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J 2001;20(7):1663-73
   PubMedGoogle Scholar
• Oshima M, Oshima H, Taketo MM. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 1996;179(1):297-302
   PubMedGoogle Scholar
• Stearns ME, Garcia FU, Fudge K, et al. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 1999;5(3):711-20
   PubMedGoogle Scholar
• Buck MB, Fritz P, Dippon J, et al. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 2004;10(2):491-8
   PubMedGoogle Scholar
• Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993;143(2):381-9
   PubMed Web of Science ®Google Scholar
• Biswas S, Guix M, Rinehart C, et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007;117(5):1305-13
   PubMed Web of Science ®Google Scholar
• Giampieri S, Manning C, Hooper S, et al. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009;11(11):1287-96
   PubMed Web of Science ®Google Scholar
• Siegel PM, Shu W, Cardiff RD, et al. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003;100(14):8430-5
   PubMedGoogle Scholar
• Forrester E, Chytil A, Bierie B, et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005;65(6):2296-302
   PubMedGoogle Scholar
• Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6(10):2609-17
   PubMed Web of Science ®Google Scholar
• Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005;102(39):13909-14
   PubMed Web of Science ®Google Scholar
• Saito H, Tsujitani S, Oka S, et al. An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000;20(6B):4489-93
   PubMed Web of Science ®Google Scholar
• Tsai JF, Jeng JE, Chuang LY, et al. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer 1997;76(2):244-50
   PubMedGoogle Scholar
• Papadopoulou E, Anagnostopoulos K, Tripsianis G, et al. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Neoplasma 2008;55(3):229-38
   PubMed Web of Science ®Google Scholar
• Saunier EF, Akhurst RJ. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 2006;6(7):565-78
   PubMed Web of Science ®Google Scholar
• Calone I, Souchelnytskyi S. Inhibition of TGFbeta signaling and its implications in anticancer treatments. Exp Oncol 2012;34(1):9-16
   PubMedGoogle Scholar
• Hau P, Jachimczak P, Schlingensiepen R, et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007;17(2):201-12
   PubMed Web of Science ®Google Scholar
• Schlingensiepen KH, Jaschinski F, Lang SA, et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci 2011;102(6):1193-200
   PubMed Web of Science ®Google Scholar
• Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, et al. TGF-beta signalling in colon carcinogenesis. Cancer Lett 2012;314(1):1-7
   PubMedGoogle Scholar
• Oettle H, Seufferlein T, Luger T, et al. Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J Clin Oncol 2012;30. [abstract: 2012 ASCO meeting]
   Google Scholar
• Nam JS, Terabe M, Mamura M, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008;68(10):3835-43
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Ge R, Grazioli A, et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 2010;9:122
   PubMed Web of Science ®Google Scholar
• Morris JC, Shapiro GI, Tan AR, et al. A human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody (mAB) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 2008;26:9028
   Google Scholar
• Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109(12):1607-15
   PubMed Web of Science ®Google Scholar
• Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109(12):1551-9
   PubMed Web of Science ®Google Scholar
• Rowland-Goldsmith MA, Maruyama H, Matsuda K, et al. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 2002;1(3):161-7
   PubMedGoogle Scholar
• Bandyopadhyay A, Zhu Y, Malik SN, et al. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 2002;21(22):3541-51
   PubMedGoogle Scholar
• van Meeteren LA, Thorikay M, Bergqvist S, et al. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem 2012;287(22):18551-61
   PubMedGoogle Scholar
• Goff LW, De Braud FG, Cohen RB, et al. Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFbeta receptor involved in tumor angiogenesis. J Clin Oncol 2012;30:e13606
   Google Scholar
• Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 2004;3(6):737-45
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Iwadate M, Kondo M, et al. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res 2003;63(22):7791-8
   PubMedGoogle Scholar
• Tanaka H, Shinto O, Yashiro M, et al. Transforming growth factor beta signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep 2010;24(6):1637-43
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Abe M, Hiasa M, et al. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One 2010;5(3):e9870
   PubMed Web of Science ®Google Scholar
• DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004;65(3):744-52
   PubMed Web of Science ®Google Scholar
• Ehata S, Hanyu A, Fujime M, et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007;98(1):127-33
   PubMed Web of Science ®Google Scholar
• Shinto O, Yashiro M, Kawajiri H, et al. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer 2010;102(5):844-51
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Agyin JK, Wang L, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006;66(13):6714-21
   PubMedGoogle Scholar
• Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64(21):7954-61
   PubMed Web of Science ®Google Scholar
• Mohammad KS, Javelaud D, Fournier PG, et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011;71(1):175-84
   PubMed Web of Science ®Google Scholar
• Melisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008;7(4):829-40
   PubMed Web of Science ®Google Scholar
• Korpal M, Yan J, Lu X, et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009;15(8):960-6
   PubMed Web of Science ®Google Scholar
• Zhang B, Halder SK, Zhang S, Datta PK. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 2009;277(1):114-20
   PubMed Web of Science ®Google Scholar
• Connolly EC, Saunier EF, Quigley D, et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761. Cancer Res 2011;71(6):2339-49
   PubMed Web of Science ®Google Scholar
• Yakymovych I, Engstrom U, Grimsby S, et al. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase. Biochemistry 2002;41(36):11000-7
   PubMedGoogle Scholar
• Bueno L, de Alwis DP, Pitou C, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 2008;44(1):142-50
   PubMed Web of Science ®Google Scholar
• Rodon Ahnert J, Baselga J, Calvo E, et al. First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. J Clin Oncol 2011;29:abstract 3011
   Google Scholar
• Zhao BM, Hoffmann FM. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell 2006;17(9):3819-31
   PubMed Web of Science ®Google Scholar
• Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5(12):997-1014
   PubMed Web of Science ®Google Scholar
• Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18(1):45-56
   PubMed Web of Science ®Google Scholar
• White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001;19(3):114-20
   PubMedGoogle Scholar
• Gupta S, Jain MM, Maru A, et al. A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. J Clin 2012;30: abstract 3011
   Google Scholar
• Shah S, Islam MN, Dakshanamurthy S, et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 2006;21(6):799-809
   PubMedGoogle Scholar
• Larriba MJ, Valle N, Palmer HG, et al. The inhibition of Wnt/beta-catenin signalling by 1alpha,25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. Endocr Relat Cancer 2007;14(1):141-51
   PubMedGoogle Scholar
• Walia B, Wang L, Merlin D, Sitaraman SV. TGF-beta down-regulates IL-6 signaling in intestinal epithelial cells: critical role of SMAD-2. Faseb J 2003;17(14):2130-2
   PubMedGoogle Scholar
• Tang Y, Kitisin K, Jogunoori W, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA 2008;105(7):2445-50
   PubMed Web of Science ®Google Scholar
• Lin L, Amin R, Gallicano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009;28(7):961-72
   PubMed Web of Science ®Google Scholar
• Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122(3):467-81
   PubMed Web of Science ®Google Scholar
• Thomas P, Forse RA, Bajenova O. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin Exp Metastasis 2011;28(8):923-32
   PubMed Web of Science ®Google Scholar
• Bajenova OV, Zimmer R, Stolper E, et al. Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells. J Biol Chem 2001;276(33):31067-73
   PubMedGoogle Scholar
• Li Y, Cao H, Jiao Z, et al. Carcinoembryonic antigen interacts with TGF-{beta} receptor and inhibits TGF-{beta} signaling in colorectal cancers. Cancer Res 2010;70(20):8159-68
   PubMedGoogle Scholar
• Roberts AB, Lamb LC, Newton DL, et al. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 1980;77(6):3494-8
   PubMed Web of Science ®Google Scholar
• Moses HL, Branum EL, Proper JA, Robinson RA. Transforming growth factor production by chemically transformed cells. Cancer Res 1981;41(7):2842-8
   PubMed Web of Science ®Google Scholar
• Deharvengt S, Marmarelis M, Korc M. Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer. PloS One 2012;7(6):e39684
   Google Scholar